HK1168284A1 - Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units - Google Patents

Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units

Info

Publication number
HK1168284A1
HK1168284A1 HK12109099.7A HK12109099A HK1168284A1 HK 1168284 A1 HK1168284 A1 HK 1168284A1 HK 12109099 A HK12109099 A HK 12109099A HK 1168284 A1 HK1168284 A1 HK 1168284A1
Authority
HK
Hong Kong
Prior art keywords
pth
osteoporosis
week
units
unit dose
Prior art date
Application number
HK12109099.7A
Other languages
English (en)
Inventor
Shinichiro Shirae
Yasuo Nakamura
Yuiko Masunaga
Yoshihide Nozaki
Nobuyuki Kobayashi
Tatsuhiko Kuroda
Hiroki Kato
Masashi Serada
Kazuyoshi Hori
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43732444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1168284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of HK1168284A1 publication Critical patent/HK1168284A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
HK12109099.7A 2009-09-09 2012-09-17 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units HK1168284A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009208039 2009-09-09
PCT/JP2010/065379 WO2011030774A1 (fr) 2009-09-09 2010-09-08 Agent thérapeutique/prophylactique contenant de la parathormone (pth) pour l'ostéoporose, caractérisé en ce que la pth est administrée une fois par semaine selon une dose unitaire de 100 à 200 unités

Publications (1)

Publication Number Publication Date
HK1168284A1 true HK1168284A1 (en) 2012-12-28

Family

ID=43732444

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12109099.7A HK1168284A1 (en) 2009-09-09 2012-09-17 Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units

Country Status (17)

Country Link
US (3) US20120252729A1 (fr)
EP (3) EP2476429B1 (fr)
JP (13) JPWO2011030774A1 (fr)
KR (8) KR102335703B1 (fr)
CN (2) CN103893746A (fr)
AU (1) AU2010293488B2 (fr)
BR (1) BR112012003511A2 (fr)
CA (1) CA2772656A1 (fr)
ES (3) ES2843649T3 (fr)
HK (1) HK1168284A1 (fr)
IL (1) IL217854A (fr)
IN (1) IN2012DN00857A (fr)
MX (1) MX335951B (fr)
NZ (2) NZ598370A (fr)
RU (1) RU2564894C2 (fr)
WO (1) WO2011030774A1 (fr)
ZA (1) ZA201201720B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616004T3 (es) * 2009-11-18 2017-06-09 Asahi Kasei Pharma Corporation Agente profiláctico y/o agente terapéutico y/o agente supresor de exacerbación para osteortritis de rodilla humana
JP6235219B2 (ja) * 2013-03-21 2017-11-22 旭化成ファーマ株式会社 脊椎椎体間固定術後の骨癒合促進剤
US10394953B2 (en) 2015-07-17 2019-08-27 Facebook, Inc. Meme detection in digital chatter analysis
JP2020506926A (ja) * 2017-02-01 2020-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 副甲状腺ホルモンと変性椎間板疾患の再生
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
CA3075984A1 (fr) * 2017-09-22 2019-03-28 Asahi Kasei Pharma Corporation Composition pharmaceutique liquide contenant de la teriparatide presentant d'excellentes proprietes pharmacocinetiques et/ou d'innocuite
WO2019059302A1 (fr) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 Composition pharmaceutique liquide contenant du tériparatide ayant une excellente stabilité
JP7080487B2 (ja) 2018-09-26 2022-06-06 東陽建設工機株式会社 鉄筋曲げ方法
CA3101326C (fr) 2018-10-29 2023-08-01 Asahi Kasei Pharma Corporation Methode de prevention ou de traitement de l'osteoporose caracterisee par l'administration de teriparatide ou d'un sel connexe a frequence de deux fois par semaine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2505812B2 (ja) 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
JP2662842B2 (ja) 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
MY120063A (en) * 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
IL153678A0 (en) 2000-06-30 2003-07-06 Suntory Ltd A pharmaceutical component comprising a human parathyroid hormone
JP5042419B2 (ja) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 骨形成促進剤および骨形成促進組成物
JP4931306B2 (ja) 2001-09-27 2012-05-16 旭化成ファーマ株式会社 骨形成を安全に促進させる医薬複合剤
EP1643978A1 (fr) * 2003-07-04 2006-04-12 Nycomed Danmark A/S Compositions pharmaceutiques contenant une hormone parathyroide (pth) administrees par voie orale
EP1741441A4 (fr) * 2004-04-26 2010-03-03 Ono Pharmaceutical Co Agent densifiant les os caracterise en ce qu'il utilise un inhibiteur de cathepsine k avec une pth
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
JP2006241098A (ja) * 2005-03-04 2006-09-14 Univ Kurume 骨量減少症の予防または治療薬
WO2007092622A2 (fr) * 2006-02-09 2007-08-16 Biomimetic Therapeutics, Inc. Compositions et méthodes pour le traitement d'os
DE102006043846A1 (de) * 2006-03-14 2007-09-20 Claudia Zours Wirbelsäulenorthesen
WO2007106597A2 (fr) * 2006-03-15 2007-09-20 Alza Corporation Appareil et procede d'administration transdermique d'agents hormonaux parathyroidiens destines a traiter ou prevenir l'osteopenie
CN101274961A (zh) * 2006-03-30 2008-10-01 天津医科大学 重组人甲状旁腺素相关蛋白
CN101125201A (zh) * 2006-08-17 2008-02-20 石家庄欧意药业有限公司 治疗骨质疏松症或防治由于骨质疏松而导致的骨折的药物组合物及其应用
CN101307105B (zh) * 2008-04-28 2012-08-29 中国药科大学 一种能串联表达和同步酸水解释放的人甲状旁腺素1-34肽类似物及其制备方法和应用

Also Published As

Publication number Publication date
JP2019023234A (ja) 2019-02-14
IL217854A0 (en) 2012-03-29
MX2012002681A (es) 2012-04-19
JP2017105858A (ja) 2017-06-15
KR20120067336A (ko) 2012-06-25
EP2682125B1 (fr) 2020-11-04
ES2843649T3 (es) 2021-07-20
EP2476429A1 (fr) 2012-07-18
CN103893746A (zh) 2014-07-02
KR20200115673A (ko) 2020-10-07
MX335951B (es) 2016-01-04
AU2010293488B2 (en) 2014-11-27
RU2564894C2 (ru) 2015-10-10
JP6275900B2 (ja) 2018-02-07
JP2018024710A (ja) 2018-02-15
JP6150846B2 (ja) 2017-06-21
KR20170089017A (ko) 2017-08-02
JP2016130261A (ja) 2016-07-21
JP2017105861A (ja) 2017-06-15
AU2010293488A1 (en) 2012-03-29
KR102424644B1 (ko) 2022-07-25
EP2682124B1 (fr) 2018-02-28
BR112012003511A2 (pt) 2019-09-24
JP6301524B2 (ja) 2018-03-28
NZ598370A (en) 2014-04-30
EP2682124A1 (fr) 2014-01-08
RU2012108635A (ru) 2013-10-20
KR20210040171A (ko) 2021-04-12
JP2017105862A (ja) 2017-06-15
JP2015157854A (ja) 2015-09-03
US20140249084A1 (en) 2014-09-04
JPWO2011030774A1 (ja) 2013-02-07
JP2017105863A (ja) 2017-06-15
EP2476429A4 (fr) 2013-02-27
WO2011030774A1 (fr) 2011-03-17
JP6198346B2 (ja) 2017-09-20
KR20190095552A (ko) 2019-08-14
JP6274634B2 (ja) 2018-02-07
ES2663322T3 (es) 2018-04-12
JP2017105859A (ja) 2017-06-15
ZA201201720B (en) 2012-11-28
JP6043008B2 (ja) 2016-12-14
IL217854A (en) 2016-08-31
KR102335703B1 (ko) 2021-12-07
KR20150021590A (ko) 2015-03-02
JP2017105860A (ja) 2017-06-15
CN102470164B (zh) 2014-04-09
ES2662018T3 (es) 2018-04-05
IN2012DN00857A (fr) 2015-07-10
US20120252729A1 (en) 2012-10-04
CN102470164A (zh) 2012-05-23
JP2015147813A (ja) 2015-08-20
EP2682125A1 (fr) 2014-01-08
NZ617397A (en) 2015-02-27
US20140357560A1 (en) 2014-12-04
KR20170089018A (ko) 2017-08-02
KR20140130754A (ko) 2014-11-11
JP2017061511A (ja) 2017-03-30
JP6522715B2 (ja) 2019-05-29
CA2772656A1 (fr) 2011-03-17
EP2476429B1 (fr) 2018-03-07

Similar Documents

Publication Publication Date Title
HK1168284A1 (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
IL234624A0 (en) Compounds for use as a drug to treat a solid tumor in a patient
PL2437829T3 (pl) Mechanizm ustawiania dawki dla urządzenia do dostarczania leku dla ograniczania ustawienia dawki odpowiadającej pozostałej ilości leku
IL239488A0 (en) A gpc3-targeted medicinal agent for the treatment of patients for whom treatment with a gpc3-targeted medicinal agent is beneficial
IL221166B (en) A system for administering medication to a patient
PT2482812T (pt) Composições farmacêuticas compreendendo bi-1356 e metformina
PL2568887T3 (pl) Urządzenie do dostarczania kompozycji leczącej tkanki do zszywanej tkanki
EP2240232A4 (fr) Distributeur et conditionnement thérapeutique pour l'administration d'une substance thérapeutique à un sujet
IL216468B (en) Pharmaceutical compounds for administration by metered dose inhaler containing glycopyrrolate and formoterol and used for the treatment of respiratory diseases
IL216668A (en) Pharmaceutical preparation and its use in the preparation of a drug for emergency contraception
IL221744A (en) Use of a combination of compounds to prepare a drug to treat Parkinson's disease
IL217777A (en) A peptide for the preparation of pain medication
IL217198A0 (en) Composition for treating a patient in need of aspirin therapy
IL215826A (en) Pharmaceutical preparation with delayed release, process of preparation of the preparation, use of the preparation for the preparation of pain medication and the pill containing it.
EP2370068A4 (fr) Procédés et compositions pour la délivrance de médicaments aux poumons
HK1199416A1 (en) A device for administering a powdered medicament to a patient by inhalation
GB2455875B (en) A process for the preparation of an orally administered unit dose tablet
IL217185A0 (en) Medicinal carbohydrates for treatment of respiratory conditions
IL217527A0 (en) Fulvestrant in a dosage of 500 mg for the treatment of advanced breast cancer
HK1154817A1 (en) Use of pump to deliver solution for reducing of snoring
GB2475701B (en) A process for the preparation of an orally administered anthelmintic unit dose tablet
IL215695A (en) Use of Compounds 1-Phenyl-3-Dimethyl Amino Propane for the preparation of rheumatic pain medication
EP2303282A4 (fr) Traitement utilisant une application continue à faible dose d analogues de sucre
MX2013010415A (es) Tratamiento de la atrofia vaginal con nueva indicacion para la mirra.
PL2424602T3 (pl) System do dostarczania środka leczniczego do skóry pacjenta